The National Institute of Dental and Craniofacial Research, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patent Applications listed in the Supplementary Information section of this notice to ERYTHRYx Therapeutics, located in Los Angeles, California.
Document
Prospective Grant of an Exclusive Patent License: Methods of Modulating Erythropoiesis With Arginine Vasopressin Receptor 1B Molecules
The National Institute of Dental and Craniofacial Research, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the gran...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
83 FR 29127
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Prospective Grant of an Exclusive Patent License: Methods of Modulating Erythropoiesis With Arginine Vasopressin Receptor 1B Molecules,” thefederalregister.org (June 22, 2018), https://thefederalregister.org/documents/2018-13443/prospective-grant-of-an-exclusive-patent-license-methods-of-modulating-erythropoiesis-with-arginine-vasopressin-receptor.